Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease

Sharma, P.; Sharma, A.; Fayaz, F.; Wakode, S.; Pottoo, F.H. Biological Signatures of Alzheimer’s Disease. Curr. Top. Med. Chem., 2020, 20(9), 770-781.
[http://dx.doi.org/10.2174/1568026620666200228095553] [PMID: 32108008]

Uddin, M.S.; Al Mamun, A.; Ashraf, G.M. Neurotoxic Aβ: Linking Extracellular and Intracellular Aβ in Alzheimer’s Disease. Curr. Protein Pept. Sci., 2021, 22, 442-448.
[PMID: 33480343]

WHO Dementia Available at: . https://www.who.int/news-room/fact-sheets/detail/dementia (accessed January 14, 2021)

Mayeux, R.; Stern, Y. Epidemiology of Alzheimer disease. Cold Spring Harb. Perspect. Med., 2012, 2(8), 2.
[http://dx.doi.org/10.1101/cshperspect.a006239] [PMID: 22908189]

Tarawneh, R.; Holtzman, D.M. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb. Perspect. Med., 2012, 2(5), a006148-a006148.
[http://dx.doi.org/10.1101/cshperspect.a006148] [PMID: 22553492]

Kinney, J.W.; Bemiller, S.M.; Murtishaw, A.S.; Leisgang, A.M.; Salazar, A.M.; Lamb, B.T. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement. (N. Y.), 2018, 4, 575-590.
[http://dx.doi.org/10.1016/j.trci.2018.06.014] [PMID: 30406177]

Uddin, M.S.; Kabir, M.T.; Rahman, M.S.; Behl, T.; Jeandet, P.; Ashraf, G.M.; Najda, A.; Bin-Jumah, M.N.; El-Seedi, H.R.; Abdel-Daim, M.M. Revisiting the amyloid cascade hypothesis: From anti-aβ therapeutics to auspicious new ways for alzheimer’s disease. Int. J. Mol. Sci., 2020, 21(16), 5858.
[http://dx.doi.org/10.3390/ijms21165858] [PMID: 32824102]

Gzil, F. Alzheimer’s disease: Psychiatric or neurological disorder? Poiesis Prax., 2009, 6, 13-26.
[http://dx.doi.org/10.1007/s10202-008-0061-3]

Zaplatic, E.; Bule, M.; Shah, S.Z.A.; Uddin, M.S.; Niaz, K. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer’s disease. Life Sci., 2019, 224, 109-119.
[http://dx.doi.org/10.1016/j.lfs.2019.03.055] [PMID: 30914316]

Chang, C.W.; Shao, E.; Mucke, L. Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science (80-. )., 2021, 371,

Janning, D.; Igaev, M.; Sündermann, F.; Brühmann, J.; Beutel, O.; Heinisch, J.J.; Bakota, L.; Piehler, J.; Junge, W.; Brandt, R. Single-molecule tracking of tau reveals fast kiss-and-hop interaction with microtubules in living neurons. Mol. Biol. Cell, 2014, 25(22), 3541-3551.
[http://dx.doi.org/10.1091/mbc.e14-06-1099] [PMID: 25165145]

Harilal, S.; Jose, J.; Parambi, D.G.T.; Kumar, R.; Mathew, G.E.; Uddin, M.S.; Kim, H.; Mathew, B. Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives. J. Pharm. Pharmacol., 2019, 71(9), 1370-1383.
[http://dx.doi.org/10.1111/jphp.13132] [PMID: 31304982]

Mamun, A.A.; Uddin, M.S.; Mathew, B.; Ashraf, G.M. Toxic tau: structural origins of tau aggregation in Alzheimer’s disease. Neural Regen. Res., 2020, 15(8), 1417-1420.
[http://dx.doi.org/10.4103/1673-5374.274329] [PMID: 31997800]

Hanisch, U-K.; Kettenmann, H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci., 2007, 10(11), 1387-1394.
[http://dx.doi.org/10.1038/nn1997] [PMID: 17965659]

Sierra, A.; Abiega, O.; Shahraz, A.; Neumann, H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front. Cell. Neurosci., 2013, 7, 6.
[http://dx.doi.org/10.3389/fncel.2013.00006] [PMID: 23386811]

Suzumura, A. Neuron-microglia interaction in neuroinflammation. Curr. Protein Pept. Sci., 2013, 14(1), 16-20.
[http://dx.doi.org/10.2174/1389203711314010004] [PMID: 23544747]

Santacruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McCowan, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash, A.; Kuskowski, M.; Hyman, B.; Hutton, M.; Ashe, K.H. Tau suppression in a neurodegenerative mouse model improves memory function.Science (80-.), , 2005, 309, 476-481.

Mondragón-Rodríguez, S.; Perry, G.; Zhu, X.; Moreira, P.I.; Acevedo-Aquino, M.C.; Williams, S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for alzheimer’s disease.Oxid. Med. Cell. Longev., 2013, 2013,

Müller, W.E.; Eckert, A.; Kurz, C.; Eckert, G.P.; Leuner, K. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease--therapeutic aspects. Mol. Neurobiol., 2010, 41(2-3), 159-171.
[http://dx.doi.org/10.1007/s12035-010-8141-5] [PMID: 20461558]

Kigerl, K.A.; de Rivero Vaccari, J.P.; Dietrich, W.D.; Popovich, P.G.; Keane, R.W. Pattern recognition receptors and central nervous system repair. Exp. Neurol., 2014, 258, 5-16.
[http://dx.doi.org/10.1016/j.expneurol.2014.01.001] [PMID: 25017883]

Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223.
[http://dx.doi.org/10.1016/S0140-6736(08)61075-2] [PMID: 18640458]

Hong, S.; Beja-Glasser, V.F.; Nfonoyim, B.M.; Frouin, A.; Li, S.; Ramakrishnan, S.; Merry, K.M.; Shi, Q.; Rosenthal, A.; Barres, B.A.; Lemere, C.A.; Selkoe, D.J.; Stevens, B. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 2016, 352(6286), 712-716.
[http://dx.doi.org/10.1126/science.aad8373] [PMID: 27033548]

Czirr, E.; Castello, N.A.; Mosher, K.I.; Castellano, J.M.; Hinkson, I.V.; Lucin, K.M.; Baeza-Raja, B.; Ryu, J.K.; Li, L.; Farina, S.N.; Belichenko, N.P.; Longo, F.M.; Akassoglou, K.; Britschgi, M.; Cirrito, J.R.; Wyss-Coray, T. Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity. J. Exp. Med., 2017, 214(4), 1081-1092.
[http://dx.doi.org/10.1084/jem.20162011] [PMID: 28298456]

McGeer, P.L.; Akiyama, H.; Itagaki, S.; McGeer, E.G. Immune system response in Alzheimer’s disease. Can. J. Neurol. Sci., 1989, 16(4)(Suppl.), 516-527.
[http://dx.doi.org/10.1017/S0317167100029863] [PMID: 2804814]

Heneka, M.T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; O’Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 2005, 128(Pt 6), 1442-1453.
[http://dx.doi.org/10.1093/brain/awh452] [PMID: 15817521]

Rodríguez, J.J.; Witton, J.; Olabarria, M.; Noristani, H.N.; Verkhratsky, A. Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer’s disease. Cell Death Dis., 2010, 1, e1-e1.
[http://dx.doi.org/10.1038/cddis.2009.2] [PMID: 21364611]

Jung, C.K.E.; Keppler, K.; Steinbach, S.; Blazquez-Llorca, L.; Herms, J. Fibrillar amyloid plaque formation precedes microglial activation. PLoS One, 2015, 10(3)e0119768
[http://dx.doi.org/10.1371/journal.pone.0119768] [PMID: 25799372]

Jana, M.; Palencia, C.A.; Pahan, K. Fibrillar amyloid-beta peptides activate microglia via tlR2: Implications for alzheimer’s disease. J. Immunol. (Baltimore, Md. 1950), 2008, 181, 7254-7262.

Richard, K.L.; Filali, M.; Préfontaine, P.; Rivest, S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. J. Neurosci., 2008, 28(22), 5784-5793.
[http://dx.doi.org/10.1523/JNEUROSCI.1146-08.2008] [PMID: 18509040]

Reed-Geaghan, E.G.; Savage, J.C.; Hise, A.G.; Landreth, G.E. CD14 and toll-like receptors 2 and 4 are required for fibrillar Abeta-stimulated microglial activation. J. Neurosci., 2009, 29(38), 11982-11992.
[http://dx.doi.org/10.1523/JNEUROSCI.3158-09.2009] [PMID: 19776284]

Apelt, J.; Schliebs, R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res., 2001, 894(1), 21-30.
[http://dx.doi.org/10.1016/S0006-8993(00)03176-0] [PMID: 11245811]

Patel, N.S.; Paris, D.; Mathura, V.; Quadros, A.N.; Crawford, F.C.; Mullan, M.J. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer’s disease. J. Neuroinflammation, 2005, 2(1), 9.
[http://dx.doi.org/10.1186/1742-2094-2-9] [PMID: 15762998]

Benzing, W.C.; Wujek, J.R.; Ward, E.K.; Shaffer, D.; Ashe, K.H.; Younkin, S.G.; Brunden, K.R. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging, 1999, 20(6), 581-589.
[http://dx.doi.org/10.1016/S0197-4580(99)00065-2] [PMID: 10674423]

Salminen, A.; Kauppinen, A.; Suuronen, T.; Kaarniranta, K.; Ojala, J. ER stress in Alzheimer’s disease: a novel neuronal trigger for inflammation and Alzheimer’s pathology. J. Neuroinflammation, 2009, 6, 41.
[http://dx.doi.org/10.1186/1742-2094-6-41] [PMID: 20035627]

Morimoto, K.; Horio, J.; Satoh, H.; Sue, L.; Beach, T.; Arita, S.; Tooyama, I.; Konishi, Y. Expression profiles of cytokines in the brains of Alzheimer’s disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. J. Alzheimers Dis., 2011, 25(1), 59-76.
[http://dx.doi.org/10.3233/JAD-2011-101815] [PMID: 21368376]

Agostinho, P.; Cunha, R.A.; Oliveira, C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr. Pharm. Des., 2010, 16(25), 2766-2778.
[http://dx.doi.org/10.2174/138161210793176572] [PMID: 20698820]

Wang, W-Y.; Tan, M-S.; Yu, J-T.; Tan, L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann. Transl. Med., 2015, 3(10), 136.
[PMID: 26207229]

McGeer, P.L.; Itagaki, S.; Tago, H.; McGeer, E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett., 1987, 79(1-2), 195-200.
[http://dx.doi.org/10.1016/0304-3940(87)90696-3] [PMID: 3670729]

Zotova, E.; Holmes, C.; Johnston, D.; Neal, J.W.; Nicoll, J.A.; Boche, D. Microglial alterations in human Alzheimer’s disease following Aβ42 immunization. Neuropathol. Appl. Neurobiol., 2011, 37(5), 513-524.
[http://dx.doi.org/10.1111/j.1365-2990.2010.01156.x] [PMID: 21166690]

Shao, Y.; Gearing, M.; Mirra, S.S. Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. J. Neuropathol. Exp. Neurol., 1997, 56(4), 376-381.
[http://dx.doi.org/10.1097/00005072-199704000-00006] [PMID: 9100668]

Uddin, M.S.; Kabir, M.T.; Mamun, A.A.; Barreto, G.E.; Rashid, M.; Perveen, A.; Ashraf, G.M. Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease. Int. Immunopharmacol., 2020, 84106479
[http://dx.doi.org/10.1016/j.intimp.2020.106479] [PMID: 32353686]

Ibrahim, A.M.; Pottoo, F.H.; Dahiya, E.S.; Khan, F.A.; Kumar, J.B.S. Neuron-glia interactions: Molecular basis of alzheimer’s disease and applications of neuroproteomics. Eur. J. Neurosci., 2020, 52(2), 2931-2943.
[http://dx.doi.org/10.1111/ejn.14838] [PMID: 32463535]

Kabir, M.T.; Uddin, M.S.; Zaman, S.; Rahman, M.S.; Behl, T.; Ahmad, A.; Hafeez, A.; Perveen, A.; Ashraf, G.M. Exploring the anti-neuroinflammatory potential of steroid and terpenoid-derived phytochemicals to combat alzheimer’s disease. Curr. Pharm. Des., 2021, 27(22), 2635-2647.
[PMID: 33463452]

Kummer, M.P.; Hammerschmidt, T.; Martinez, A.; Terwel, D.; Eichele, G.; Witten, A.; Figura, S.; Stoll, M.; Schwartz, S.; Pape, H-C.; Schultze, J.L.; Weinshenker, D.; Heneka, M.T.; Urban, I. Ear2 deletion causes early memory and learning deficits in APP/PS1 mice. J. Neurosci., 2014, 34(26), 8845-8854.
[http://dx.doi.org/10.1523/JNEUROSCI.4027-13.2014] [PMID: 24966384]

Gahtan, E.; Overmier, J.B. Inflammatory pathogenesis in Alzheimer’s disease: biological mechanisms and cognitive sequeli. Neurosci. Biobehav. Rev., 1999, 23(5), 615-633.
[http://dx.doi.org/10.1016/S0149-7634(98)00058-X] [PMID: 10392655]

Ii, M.; Sunamoto, M.; Ohnishi, K.; Ichimori, Y. β-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. Brain Res., 1996, 720(1-2), 93-100.
[http://dx.doi.org/10.1016/0006-8993(96)00156-4] [PMID: 8782901]

Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O’Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer’s disease. Neurobiol. Aging, 2000, 21(3), 383-421.
[http://dx.doi.org/10.1016/S0197-4580(00)00124-X] [PMID: 10858586]

Heneka, M.T.; O’Banion, M.K. Inflammatory processes in Alzheimer’s disease. J. Neuroimmunol., 2007, 184(1-2), 69-91.
[http://dx.doi.org/10.1016/j.jneuroim.2006.11.017] [PMID: 17222916]

Rojo, L.E.; Fernández, J.A.; Maccioni, A.A.; Jimenez, J.M.; Maccioni, R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch. Med. Res., 2008, 39(1), 1-16.
[http://dx.doi.org/10.1016/j.arcmed.2007.10.001] [PMID: 18067990]

Hoozemans, J.J.M.; Veerhuis, R.; Rozemuller, J.M.; Eikelenboom, P. Neuroinflammation and regeneration in the early stages of Alzheimer’s disease pathology. Int. J. Dev. Neurosci., 2006, 24(2-3), 157-165.
[http://dx.doi.org/10.1016/j.ijdevneu.2005.11.001] [PMID: 16384684]

Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med., 2006, 12(9), 1005-1015.
[PMID: 16960575]

Clayton, K.A.; Van Enoo, A.A.; Ikezu, T. Alzheimer’s disease: The role of microglia in brain homeostasis and proteopathy. Front. Neurosci., 2017, 11, 680.
[http://dx.doi.org/10.3389/fnins.2017.00680] [PMID: 29311768]

Versijpt, J.J.; Dumont, F.; Van Laere, K.J.; Decoo, D.; Santens, P.; Audenaert, K.; Achten, E.; Slegers, G.; Dierckx, R.A.; Korf, J. Assessment of neuroinflammation and microglial activation in Alzheimer’s disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol., 2003, 50(1), 39-47.
[http://dx.doi.org/10.1159/000070857] [PMID: 12824711]

Edison, P.; Archer, H.A.; Gerhard, A.; Hinz, R.; Pavese, N.; Turkheimer, F.E.; Hammers, A.; Tai, Y.F.; Fox, N.; Kennedy, A.; Rossor, M.; Brooks, D.J. Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis., 2008, 32(3), 412-419.
[http://dx.doi.org/10.1016/j.nbd.2008.08.001] [PMID: 18786637]

Wiley, C.A.; Lopresti, B.J.; Venneti, S.; Price, J.; Klunk, W.E.; DeKosky, S.T.; Mathis, C.A. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch. Neurol., 2009, 66(1), 60-67.
[http://dx.doi.org/10.1001/archneurol.2008.511] [PMID: 19139300]

Venneti, S.; Lopresti, B.J.; Wang, G.; Hamilton, R.L.; Mathis, C.A.; Klunk, W.E.; Apte, U.M.; Wiley, C.A. PK11195 labels activated microglia in Alzheimer’s disease and in vivo in a mouse model using PET. Neurobiol. Aging, 2009, 30(8), 1217-1226.
[http://dx.doi.org/10.1016/j.neurobiolaging.2007.11.005] [PMID: 18178291]

Bamberger, M.E.; Harris, M.E.; McDonald, D.R.; Husemann, J.; Landreth, G.E. A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation. J. Neurosci., 2003, 23(7), 2665-2674.
[http://dx.doi.org/10.1523/JNEUROSCI.23-07-02665.2003] [PMID: 12684452]

Carty, M.; Bowie, A.G. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem. Pharmacol., 2011, 81(7), 825-837.
[http://dx.doi.org/10.1016/j.bcp.2011.01.003] [PMID: 21241665]

Arancio, O.; Zhang, H.P.; Chen, X.; Lin, C.; Trinchese, F.; Puzzo, D.; Liu, S.; Hegde, A.; Yan, S.F.; Stern, A.; Luddy, J.S.; Lue, L.F.; Walker, D.G.; Roher, A.; Buttini, M.; Mucke, L.; Li, W.; Schmidt, A.M.; Kindy, M.; Hyslop, P.A.; Stern, D.M.; Du Yan, S.S. Rage potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J., 2004, 23(20), 4096-4105.
[http://dx.doi.org/10.1038/sj.emboj.7600415] [PMID: 15457210]

Koenigsknecht-Talboo, J.; Landreth, G.E. Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci., 2005, 25(36), 8240-8249.
[http://dx.doi.org/10.1523/JNEUROSCI.1808-05.2005] [PMID: 16148231]

El Khoury, J.B.; Moore, K.J.; Means, T.K.; Leung, J.; Terada, K.; Toft, M.; Freeman, M.W.; Luster, A.D. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med., 2003, 197(12), 1657-1666.
[http://dx.doi.org/10.1084/jem.20021546] [PMID: 12796468]

Lue, L.F.; Brachova, L.; Civin, W.H. Rogers, J. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J. Neuropathol. Exp. Neurol., 1996, 55(10), 1083-1088.
[http://dx.doi.org/10.1097/00005072-199655100-00008] [PMID: 8858005]

Schilling, T.; Eder, C. Amyloid-β-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia. J. Cell. Physiol., 2011, 226(12), 3295-3302.
[http://dx.doi.org/10.1002/jcp.22675] [PMID: 21321937]

Shaftel, S.S.; Kyrkanides, S.; Olschowka, J.A.; Miller, J.N.; Johnson, R.E.; O’Banion, M.K. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest., 2007, 117(6), 1595-1604.
[http://dx.doi.org/10.1172/JCI31450] [PMID: 17549256]

Chakrabarty, P.; Jansen-West, K.; Beccard, A.; Ceballos-Diaz, C.; Levites, Y.; Verbeeck, C.; Zubair, A.C.; Dickson, D.; Golde, T.E.; Das, P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J., 2010, 24(2), 548-559.
[http://dx.doi.org/10.1096/fj.09-141754] [PMID: 19825975]

Decourt, B.; Lahiri, D.K.; Sabbagh, M.N. Targeting tumor necrosis factor alpha for alzheimer’s disease. Curr. Alzheimer Res., 2017, 14(4), 412-425.
[http://dx.doi.org/10.2174/1567205013666160930110551] [PMID: 27697064]

Ramos, E.M.; Lin, M.T.; Larson, E.B.; Maezawa, I.; Tseng, L.H.; Edwards, K.L.; Schellenberg, G.D.; Hansen, J.A.; Kukull, W.A.; Jin, L.W. Tumor necrosis factor α and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch. Neurol., 2006, 63(8), 1165-1169.
[http://dx.doi.org/10.1001/archneur.63.8.1165] [PMID: 16908746]

Janelsins, M.C.; Mastrangelo, M.A.; Park, K.M.; Sudol, K.L.; Narrow, W.C.; Oddo, S.; LaFerla, F.M.; Callahan, L.M.; Federoff, H.J.; Bowers, W.J. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am. J. Pathol., 2008, 173(6), 1768-1782.
[http://dx.doi.org/10.2353/ajpath.2008.080528] [PMID: 18974297]

Yin, Y.; Ren, Y.; Wu, W.; Wang, Y.; Cao, M.; Zhu, Z.; Wang, M.; Li, W. Protective effects of bilobalide on Aβ(25-35) induced learning and memory impairments in male rats. Pharmacol. Biochem. Behav., 2013, 106, 77-84.
[http://dx.doi.org/10.1016/j.pbb.2013.03.005] [PMID: 23537729]

Tobinick, E. Tumour necrosis factor modulation for treatment of alzheimerʼs disease. CNS Drugs, 2009, 23, 713-725.
[http://dx.doi.org/10.2165/11310810-000000000-00000] [PMID: 19689163]

Shin, J-W.; Cheong, Y-J.; Koo, Y-M.; Kim, S.; Noh, C-K.; Son, Y-H.; Kang, C.; Sohn, N-W. α-asarone ameliorates memory deficit in lipopolysaccharide-treated mice via suppression of pro-inflammatory cytokines and microglial activation. Biomol. Ther. (Seoul), 2014, 22(1), 17-26.
[http://dx.doi.org/10.4062/biomolther.2013.102] [PMID: 24596617]

Bremer, E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol., 2013, 2013371854
[http://dx.doi.org/10.1155/2013/371854] [PMID: 23840967]

Montgomery, S.L.; Narrow, W.C.; Mastrangelo, M.A.; Olschowka, J.A.; O’Banion, M.K.; Bowers, W.J. Chronic neuron- and age-selective down-regulation of TNF receptor expression in triple-transgenic Alzheimer disease mice leads to significant modulation of amyloid- and Tau-related pathologies. Am. J. Pathol., 2013, 182(6), 2285-2297.
[http://dx.doi.org/10.1016/j.ajpath.2013.02.030] [PMID: 23567638]

He, P.; Zhong, Z.; Lindholm, K.; Berning, L.; Lee, W.; Lemere, C.; Staufenbiel, M.; Li, R.; Shen, Y. Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer’s mice. J. Cell Biol., 2007, 178(5), 829-841.
[http://dx.doi.org/10.1083/jcb.200705042] [PMID: 17724122]

McAlpine, F.E.; Lee, J-K.; Harms, A.S.; Ruhn, K.A.; Blurton-Jones, M.; Hong, J.; Das, P.; Golde, T.E.; LaFerla, F.M.; Oddo, S.; Blesch, A.; Tansey, M.G. Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis., 2009, 34(1), 163-177.
[http://dx.doi.org/10.1016/j.nbd.2009.01.006] [PMID: 19320056]

Montgomery, S.L.; Mastrangelo, M.A.; Habib, D.; Narrow, W.C.; Knowlden, S.A.; Wright, T.W.; Bowers, W.J. Ablation of TNF-RI/RII expression in Alzheimer’s disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain. Am. J. Pathol., 2011, 179(4), 2053-2070.
[http://dx.doi.org/10.1016/j.ajpath.2011.07.001] [PMID: 21835156]

Barger, S.W.; Hörster, D.; Furukawa, K.; Goodman, Y.; Krieglstein, J.; Mattson, M.P. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. USA, 1995, 92(20), 9328-9332.
[http://dx.doi.org/10.1073/pnas.92.20.9328] [PMID: 7568127]

Tarkowski, E.; Blennow, K.; Wallin, A.; Tarkowski, A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol., 1999, 19(4), 223-230.
[http://dx.doi.org/10.1023/A:1020568013953] [PMID: 10471976]

Kaneko, N.; Kurata, M.; Yamamoto, T.; Morikawa, S.; Masumoto, J. The role of interleukin-1 in general pathology. Inflamm. Regen., 2019, 39, 12.
[http://dx.doi.org/10.1186/s41232-019-0101-5] [PMID: 31182982]

Shaftel, S.S.; Griffin, W.S.T.; O’Banion, M.K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J. Neuroinflammation, 2008, 5, 7.
[http://dx.doi.org/10.1186/1742-2094-5-7] [PMID: 18302763]

Lamkanfi, M.; Dixit, V.M. Inflammasomes and their roles in health and disease. Annu. Rev. Cell Dev. Biol., 2012, 28, 137-161.
[http://dx.doi.org/10.1146/annurev-cellbio-101011-155745] [PMID: 22974247]

Liu, L.; Martin, R.; Chan, C. Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases. Neurobiol. Aging, 2013, 34(2), 540-550.
[http://dx.doi.org/10.1016/j.neurobiolaging.2012.05.017] [PMID: 22727944]

Parajuli, B.; Sonobe, Y.; Horiuchi, H.; Takeuchi, H.; Mizuno, T.; Suzumura, A. Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer’s disease. Cell Death Dis., 2013, 4, e975-e975.
[http://dx.doi.org/10.1038/cddis.2013.503] [PMID: 24357806]

Boutajangout, A.; Wisniewski, T. The innate immune system in Alzheimer’s disease. Int. J. Cell Biol., 2013, 2013576383
[http://dx.doi.org/10.1155/2013/576383] [PMID: 24223593]

Hunter, J.M.; Kwan, J.; Malek-Ahmadi, M.; Maarouf, C.L.; Kokjohn, T.A.; Belden, C.; Sabbagh, M.N.; Beach, T.G.; Roher, A.E. Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer’s disease. PLoS One, 2012, 7(5)e36893
[http://dx.doi.org/10.1371/journal.pone.0036893] [PMID: 22615835]

Sheng, J.G.; Zhu, S.G.; Jones, R.A.; Griffin, W.S.T.; Mrak, R.E. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol., 2000, 163(2), 388-391.
[http://dx.doi.org/10.1006/exnr.2000.7393] [PMID: 10833312]

Kitazawa, M.; Cheng, D.; Tsukamoto, M.R.; Koike, M.A.; Wes, P.D.; Vasilevko, V.; Cribbs, D.H.; LaFerla, F.M. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer’s disease model. J. Immunol., 2011, 187(12), 6539-6549.
[http://dx.doi.org/10.4049/jimmunol.1100620] [PMID: 22095718]

Pickering, M.; O’Connor, J.J. Pro-inflammatory cytokines and their effects in the dentate gyrus., 2007.
[http://dx.doi.org/10.1016/S0079-6123(07)63020-9]

Rubio-Perez, J.M.; Morillas-Ruiz, J.M.A. A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal, 2012, 2012756357
[http://dx.doi.org/10.1100/2012/756357] [PMID: 22566778]

Heneka, M.T.; Nadrigny, F.; Regen, T.; Martinez-Hernandez, A.; Dumitrescu-Ozimek, L.; Terwel, D.; Jardanhazi-Kurutz, D.; Walter, J.; Kirchhoff, F.; Hanisch, U-K.; Kummer, M.P. Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. USA, 2010, 107(13), 6058-6063.
[http://dx.doi.org/10.1073/pnas.0909586107] [PMID: 20231476]

Wang, Y.; Jin, S.; Sonobe, Y.; Cheng, Y.; Horiuchi, H.; Parajuli, B.; Kawanokuchi, J.; Mizuno, T.; Takeuchi, H.; Suzumura, A. Interleukin-1β induces blood-brain barrier disruption by downregulating Sonic hedgehog in astrocytes. PLoS One, 2014, 9(10)e110024
[http://dx.doi.org/10.1371/journal.pone.0110024] [PMID: 25313834]

Shaftel, S.S.; Kyrkanides, S.; Olschowka, J.A.; Miller, J.N.; Johnson, R.E.; O’Banion, M.K. Sustained hippocampal IL-1 β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest., 2007, 117(6), 1595-1604.
[http://dx.doi.org/10.1172/JCI31450] [PMID: 17549256]

Ghosh, S.; Wu, M.D.; Shaftel, S.S.; Kyrkanides, S.; LaFerla, F.M.; Olschowka, J.A.; O’Banion, M.K. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J. Neurosci., 2013, 33(11), 5053-5064.
[http://dx.doi.org/10.1523/JNEUROSCI.4361-12.2013] [PMID: 23486975]

Tachida, Y.; Nakagawa, K.; Saito, T.; Saido, T.C.; Honda, T.; Saito, Y.; Murayama, S.; Endo, T.; Sakaguchi, G.; Kato, A.; Kitazume, S.; Hashimoto, Y. Interleukin-1 β up-regulates TACE to enhance α-cleavage of APP in neurons: resulting decrease in Abeta production. J. Neurochem., 2008, 104(5), 1387-1393.
[http://dx.doi.org/10.1111/j.1471-4159.2007.05127.x] [PMID: 18021299]

Wu, Y.Y.; Hsu, J.L.; Wang, H.C.; Wu, S.J.; Hong, C.J.; Cheng, I.H.J. Alterations of the neuroinflammatory markers il-6 and trail in alzheimer’s disease. Dement. Geriatr. Cogn. Disord. Extra, 2015, 5(3), 424-434.
[http://dx.doi.org/10.1159/000439214] [PMID: 26675645]

Querfurth, H.W.; LaFerla, F.M. Alzheimer’s disease. N. Engl. J. Med., 2010, 362(4), 329-344.
[http://dx.doi.org/10.1056/NEJMra0909142] [PMID: 20107219]

Huell, M.; Strauss, S.; Volk, B.; Berger, M.; Bauer, J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer’s disease patients. Acta Neuropathol., 1995, 89(6), 544-551.
[http://dx.doi.org/10.1007/BF00571510] [PMID: 7676810]

Spooren, A.; Kolmus, K.; Laureys, G.; Clinckers, R.; De Keyser, J.; Haegeman, G.; Gerlo, S. Interleukin-6, a mental cytokine. Brain Res. Brain Res. Rev., 2011, 67(1-2), 157-183.
[http://dx.doi.org/10.1016/j.brainresrev.2011.01.002] [PMID: 21238488]

Vukic, V.; Callaghan, D.; Walker, D.; Lue, L-F.; Liu, Q.Y.; Couraud, P-O.; Romero, I.A.; Weksler, B.; Stanimirovic, D.B.; Zhang, W. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer’s brain is mediated by the JNK-AP1 signaling pathway. Neurobiol. Dis., 2009, 34(1), 95-106.
[http://dx.doi.org/10.1016/j.nbd.2008.12.007] [PMID: 19162185]

Flynn, C.M.; Garbers, Y.; Lokau, J.; Wesch, D.; Schulte, D.M.; Laudes, M.; Lieb, W.; Aparicio-Siegmund, S.; Garbers, C. Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling. Sci. Rep., 2019, 9(1), 7306.
[http://dx.doi.org/10.1038/s41598-019-43617-5] [PMID: 31086276]

Quintanilla, R.A.; Orellana, D.I.; González-Billault, C.; Maccioni, R.B. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp. Cell Res., 2004, 295(1), 245-257.
[http://dx.doi.org/10.1016/j.yexcr.2004.01.002] [PMID: 15051507]

Yirmiya, R.; Goshen, I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun., 2011, 25(2), 181-213.
[http://dx.doi.org/10.1016/j.bbi.2010.10.015] [PMID: 20970492]

Weaver, J.D.; Huang, M-H.; Albert, M.; Harris, T.; Rowe, J.W.; Seeman, T.E. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology, 2002, 59(3), 371-378.
[http://dx.doi.org/10.1212/WNL.59.3.371] [PMID: 12177370]

Dugan, L.L.; Ali, S.S.; Shekhtman, G.; Roberts, A.J.; Lucero, J.; Quick, K.L.; Behrens, M.M. IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase. PLoS One, 2009, 4(5)e5518
[http://dx.doi.org/10.1371/journal.pone.0005518] [PMID: 19436757]

Donegan, J.J.; Girotti, M.; Weinberg, M.S.; Morilak, D.A. A novel role for brain interleukin-6: Facilitation of cognitive flexibility in rat orbitofrontal cortex. J. Neurosci., 2014, 34(3), 953-962.
[http://dx.doi.org/10.1523/JNEUROSCI.3968-13.2014] [PMID: 24431453]

Sivakumar, P.V.; Westrich, G.M.; Kanaly, S.; Garka, K.; Born, T.L.; Derry, J.M.J.; Viney, J.L. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut, 2002, 50(6), 812-820.
[http://dx.doi.org/10.1136/gut.50.6.812] [PMID: 12010883]

Dinarello, C.A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol., 2007, 27(1), 98-114.
[http://dx.doi.org/10.1016/j.semnephrol.2006.09.013] [PMID: 17336692]

Sutinen, E.M.; Pirttilä, T.; Anderson, G.; Salminen, A.; Ojala, J.O. Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J. Neuroinflammation, 2012, 9, 199.
[http://dx.doi.org/10.1186/1742-2094-9-199] [PMID: 22898493]

Ghayur, T.; Banerjee, S.; Hugunin, M.; Butler, D.; Herzog, L.; Carter, A.; Quintal, L.; Sekut, L.; Talanian, R.; Paskind, M.; Wong, W.; Kamen, R.; Tracey, D.; Allen, H. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature, 1997, 386(6625), 619-623.
[http://dx.doi.org/10.1038/386619a0] [PMID: 9121587]

Fantuzzi, G.; Dinarello, C.A. Interleukin-18 and interleukin-1 β: Two cytokine substrates for ICE (caspase-1). J. Clin. Immunol., 1999, 19(1), 1-11.
[http://dx.doi.org/10.1023/A:1020506300324] [PMID: 10080100]

Ojala, J.; Alafuzoff, I.; Herukka, S.K.; van Groen, T.; Tanila, H.; Pirttilä, T. Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol. Aging, 2009, 30(2), 198-209.
[http://dx.doi.org/10.1016/j.neurobiolaging.2007.06.006] [PMID: 17658666]

Curran, B.; O’Connor, J.J. The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience, 2001, 108(1), 83-90.
[http://dx.doi.org/10.1016/S0306-4522(01)00405-5] [PMID: 11738133]

Alboni, S.; Cervia, D.; Sugama, S.; Conti, B. Interleukin 18 in the CNS. J. Neuroinflammation, 2010, 7, 9.
[http://dx.doi.org/10.1186/1742-2094-7-9] [PMID: 20113500]

Rex, D.A.B.; Agarwal, N.; Prasad, T.S.K.; Kandasamy, R.K.; Subbannayya, Y.; Pinto, S.M. A comprehensive pathway map of IL-18-mediated signalling. J. Cell Commun. Signal., 2020, 14(2), 257-266.
[http://dx.doi.org/10.1007/s12079-019-00544-4] [PMID: 31863285]

Chandrasekar, B.; Valente, A.J.; Freeman, G.L.; Mahimainathan, L.; Mummidi, S. Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappaB-dependent PTEN activation. Biochem. Biophys. Res. Commun., 2006, 339(3), 956-963.
[http://dx.doi.org/10.1016/j.bbrc.2005.11.100] [PMID: 16325763]

Yu, J-T.; Chang, R.C-C.; Tan, L. Calcium dysregulation in Alzheimer’s disease: from mechanisms to therapeutic opportunities. Prog. Neurobiol., 2009, 89(3), 240-255.
[http://dx.doi.org/10.1016/j.pneurobio.2009.07.009] [PMID: 19664678]

Frayling, T.M.; Rafiq, S.; Murray, A.; Hurst, A.J.; Weedon, M.N.; Henley, W.; Bandinelli, S.; Corsi, A-M.; Ferrucci, L.; Guralnik, J.M.; Wallace, R.B.; Melzer, D. An interleukin-18 polymorphism is associated with reduced serum concentrations and better physical functioning in older people. J. Gerontol. A Biol. Sci. Med. Sci., 2007, 62(1), 73-78.
[http://dx.doi.org/10.1093/gerona/62.1.73] [PMID: 17301041]

Bossù, P.; Ciaramella, A.; Salani, F.; Vanni, D.; Palladino, I.; Caltagirone, C.; Scapigliati, G. Interleukin-18, from neuroinflammation to Alzheimer’s disease. Curr. Pharm. Des., 2010, 16(38), 4213-4224.
[http://dx.doi.org/10.2174/138161210794519147] [PMID: 21184660]

Ojala, J.O.; Sutinen, E.M.; Salminen, A.; Pirttilä, T. Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. J. Neuroimmunol., 2008, 205(1-2), 86-93.
[http://dx.doi.org/10.1016/j.jneuroim.2008.09.012] [PMID: 18947885]

Savarin-Vuaillat, C.; Ransohoff, R.M. Chemokines and chemokine receptors in neurological disease: Raise, retain, or reduce? Neurotherapeutics, 2007, 4(4), 590-601.
[http://dx.doi.org/10.1016/j.nurt.2007.07.004] [PMID: 17920540]

Xia, M.Q.; Qin, S.X.; Wu, L.J.; Mackay, C.R.; Hyman, B.T. Immunohistochemical study of the β-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer’s disease brains. Am. J. Pathol., 1998, 153(1), 31-37.
[http://dx.doi.org/10.1016/S0002-9440(10)65542-3] [PMID: 9665462]

Ishizuka, K.; Kimura, T.; Igata-yi, R.; Katsuragi, S.; Takamatsu, J.; Miyakawa, T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry Clin. Neurosci., 1997, 51(3), 135-138.
[http://dx.doi.org/10.1111/j.1440-1819.1997.tb02375.x] [PMID: 9225377]

Smits, H.A.; Rijsmus, A.; van Loon, J.H.; Wat, J.W.Y.; Verhoef, J.; Boven, L.A.; Nottet, H.S.L.M. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol., 2002, 127(1-2), 160-168.
[http://dx.doi.org/10.1016/S0165-5728(02)00112-1] [PMID: 12044988]

Lue, L.F.; Walker, D.G.; Rogers, J. Modeling microglial activation in Alzheimer’s disease with human postmortem microglial cultures. Neurobiol. Aging, 2001, 22(6), 945-956.
[http://dx.doi.org/10.1016/S0197-4580(01)00311-6] [PMID: 11755003]

Fuhrmann, M.; Bittner, T.; Jung, C.K.E.; Burgold, S.; Page, R.M.; Mitteregger, G.; Haass, C.; LaFerla, F.M.; Kretzschmar, H.; Herms, J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer’s disease. Nat. Neurosci., 2010, 13(4), 411-413.
[http://dx.doi.org/10.1038/nn.2511] [PMID: 20305648]

Lee, S.; Varvel, N.H.; Konerth, M.E.; Xu, G.; Cardona, A.E.; Ransohoff, R.M.; Lamb, B.T. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer’s disease mouse models. Am. J. Pathol., 2010, 177(5), 2549-2562.
[http://dx.doi.org/10.2353/ajpath.2010.100265] [PMID: 20864679]

Cho, S-H.; Sun, B.; Zhou, Y.; Kauppinen, T.M.; Halabisky, B.; Wes, P.; Ransohoff, R.M.; Gan, L. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem., 2011, 286(37), 32713-32722.
[http://dx.doi.org/10.1074/jbc.M111.254268] [PMID: 21771791]

Kiyota, T.; Yamamoto, M.; Xiong, H.; Lambert, M.P.; Klein, W.L.; Gendelman, H.E.; Ransohoff, R.M.; Ikezu, T. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One, 2009, 4(7)e6197
[http://dx.doi.org/10.1371/journal.pone.0006197] [PMID: 19593388]

Semple, B.D.; Frugier, T.; Morganti-Kossmann, M.C. CCL2 modulates cytokine production in cultured mouse astrocytes. J. Neuroinflammation, 2010, 7, 67.
[http://dx.doi.org/10.1186/1742-2094-7-67] [PMID: 20942978]

El Khoury, J.; Toft, M.; Hickman, S.E.; Means, T.K.; Terada, K.; Geula, C.; Luster, A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med., 2007, 13(4), 432-438.
[http://dx.doi.org/10.1038/nm1555] [PMID: 17351623]

Van Opdenbosch, N.; Lamkanfi, M. Caspases in cell death, inflammation, and disease. Immunity, 2019, 50(6), 1352-1364.
[http://dx.doi.org/10.1016/j.immuni.2019.05.020] [PMID: 31216460]

Venero, J.L.; Burguillos, M.A.; Joseph, B. Caspases playing in the field of neuroinflammation: Old and new players. Proc. Devel. Neurosci., 2013, 35, 88-101.
[http://dx.doi.org/10.1159/000346155]

Schroder, K.; Tschopp, J. The inflammasomes. Cell, 2010, 140(6), 821-832.
[http://dx.doi.org/10.1016/j.cell.2010.01.040] [PMID: 20303873]

van de Veerdonk, F.L.; Netea, M.G.; Dinarello, C.A.; Joosten, L.A.B. Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol., 2011, 32(3), 110-116.
[http://dx.doi.org/10.1016/j.it.2011.01.003] [PMID: 21333600]

Halle, A.; Hornung, V.; Petzold, G.C.; Stewart, C.R.; Monks, B.G.; Reinheckel, T.; Fitzgerald, K.A.; Latz, E.; Moore, K.J.; Golenbock, D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol., 2008, 9(8), 857-865.
[http://dx.doi.org/10.1038/ni.1636] [PMID: 18604209]

Heneka, M.T.; Kummer, M.P.; Stutz, A.; Delekate, A.; Schwartz, S.; Vieira-Saecker, A.; Griep, A.; Axt, D.; Remus, A.; Tzeng, T-C.; Gelpi, E.; Halle, A.; Korte, M.; Latz, E.; Golenbock, D.T. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature, 2013, 493(7434), 674-678.
[http://dx.doi.org/10.1038/nature11729] [PMID: 23254930]

Fricker, M.; Vilalta, A.; Tolkovsky, A.M.; Brown, G.C. Caspase inhibitors protect neurons by enabling selective necroptosis of inflamed microglia. J. Biol. Chem., 2013, 288(13), 9145-9152.
[http://dx.doi.org/10.1074/jbc.M112.427880] [PMID: 23386613]

Burguillos, M.A.; Deierborg, T.; Kavanagh, E.; Persson, A.; Hajji, N.; Garcia-Quintanilla, A.; Cano, J.; Brundin, P.; Englund, E.; Venero, J.L.; Joseph, B. Caspase signalling controls microglia activation and neurotoxicity. Nature, 2011, 472(7343), 319-324.
[http://dx.doi.org/10.1038/nature09788] [PMID: 21389984]

Rohn, T.T.; Kokoulina, P.; Eaton, C.R.; Poon, W.W. Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int. J. Clin. Exp. Med., 2009, 2(4), 300-308.
[PMID: 20057974]

Biscaro, B.; Lindvall, O.; Tesco, G.; Ekdahl, C.T.; Nitsch, R.M. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer’s disease. Neurodegener. Dis., 2012, 9(4), 187-198.
[http://dx.doi.org/10.1159/000330363] [PMID: 22584394]

Ricciotti, E.; FitzGerald, G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol., 2011, 31(5), 986-1000.
[http://dx.doi.org/10.1161/ATVBAHA.110.207449] [PMID: 21508345]

Choi, S-H.; Aid, S.; Caracciolo, L.; Minami, S.S.; Niikura, T.; Matsuoka, Y.; Turner, R.S.; Mattson, M.P.; Bosetti, F. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J. Neurochem., 2013, 124(1), 59-68.
[http://dx.doi.org/10.1111/jnc.12059] [PMID: 23083210]

Montine, T.J.; Sidell, K.R.; Crews, B.C.; Markesbery, W.R.; Marnett, L.J.; Roberts, L.J., II; Morrow, J.D. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology, 1999, 53(7), 1495-1498.
[http://dx.doi.org/10.1212/WNL.53.7.1495] [PMID: 10534257]

Slawik, H.; Volk, B.; Fiebich, B.; Hüll, M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem. Int., 2004, 45(5), 653-660.
[http://dx.doi.org/10.1016/j.neuint.2004.04.007] [PMID: 15234107]

Shie, F-S.; Montine, K.S.; Breyer, R.M.; Montine, T.J. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol., 2005, 15(2), 134-138.
[http://dx.doi.org/10.1111/j.1750-3639.2005.tb00509.x] [PMID: 15912885]

Liang, X.; Wang, Q.; Hand, T.; Wu, L.; Breyer, R.M.; Montine, T.J.; Andreasson, K. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer’s disease. J. Neurosci., 2005, 25(44), 10180-10187.
[http://dx.doi.org/10.1523/JNEUROSCI.3591-05.2005] [PMID: 16267225]

Shi, J.; Wang, Q.; Johansson, J.U.; Liang, X.; Woodling, N.S.; Priyam, P.; Loui, T.M.; Merchant, M.; Breyer, R.M.; Montine, T.J.; Andreasson, K. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann. Neurol., 2012, 72(5), 788-798.
[http://dx.doi.org/10.1002/ana.23677] [PMID: 22915243]

Xiang, Z.; Ho, L.; Yemul, S.; Zhao, Z.; Qing, W.; Pompl, P.; Kelley, K.; Dang, A.; Qing, W.; Teplow, D.; Pasinetti, G.M. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer’s disease neuropathology. Gene Expr., 2002, 10(5-6), 271-278.
[http://dx.doi.org/10.3727/000000002783992352] [PMID: 12450219]

Woodling, N.S.; Wang, Q.; Priyam, P.G.; Larkin, P.; Shi, J.; Johansson, J.U.; Zagol-Ikapitte, I.; Boutaud, O.; Andreasson, K.I. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J. Neurosci., 2014, 34(17), 5882-5894.
[http://dx.doi.org/10.1523/JNEUROSCI.0410-14.2014] [PMID: 24760848]

Bazan, N.G.; Molina, M.F.; Gordon, W.C. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu. Rev. Nutr., 2011, 31, 321-351.
[http://dx.doi.org/10.1146/annurev.nutr.012809.104635] [PMID: 21756134]

Lukiw, W.J.; Cui, J-G.; Marcheselli, V.L.; Bodker, M.; Botkjaer, A.; Gotlinger, K.; Serhan, C.N.; Bazan, N.G. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest., 2005, 115(10), 2774-2783.
[http://dx.doi.org/10.1172/JCI25420] [PMID: 16151530]

Bazan, N.G. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer’s disease. J. Lipid Res., 2009, 50(Suppl.), S400-S405.
[http://dx.doi.org/10.1194/jlr.R800068-JLR200] [PMID: 19018037]

Zhao, Y.; Calon, F.; Julien, C.; Winkler, J.W.; Petasis, N.A.; Lukiw, W.J.; Bazan, N.G. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer’s disease models. PLoS One, 2011, 6(1)e15816
[http://dx.doi.org/10.1371/journal.pone.0015816] [PMID: 21246057]

Alawieh, A.; Langley, E.F.; Weber, S.; Adkins, D.; Tomlinson, S. Identifying the role of complement in triggering neuroinflammation after traumatic brain injury. J. Neurosci., 2018, 38(10), 2519-2532.
[http://dx.doi.org/10.1523/JNEUROSCI.2197-17.2018] [PMID: 29437855]

Dunkelberger, J.R.; Song, W.C. Complement and its role in innate and adaptive immune responses. Cell Res., 2010, 20(1), 34-50.
[http://dx.doi.org/10.1038/cr.2009.139] [PMID: 20010915]

Veerhuis, R.; Nielsen, H.M.; Tenner, A.J. Complement in the brain. Mol. Immunol., 2011, 48(14), 1592-1603.
[http://dx.doi.org/10.1016/j.molimm.2011.04.003] [PMID: 21546088]

Strohmeyer, R.; Ramirez, M.; Cole, G.J.; Mueller, K.; Rogers, J. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer’s disease brain. J. Neuroimmunol., 2002, 131(1-2), 135-146.
[http://dx.doi.org/10.1016/S0165-5728(02)00272-2] [PMID: 12458045]

Yakupova, E.I.; Bobyleva, L.G.; Vikhlyantsev, I.M.; Bobylev, A.G. Complement system activation by amyloid aggregates of Aβ(1-40) and Aβ(1-42) peptides: facts and hypotheses. Biophys. Russian Fed., 2020, 65, 18-21.

Emmerling, M.R.; Watson, M.D.; Raby, C.A.; Spiegel, K. The role of complement in Alzheimer’s disease pathology. Biochim. Biophys. Acta, 2000, 1502(1), 158-171.
[http://dx.doi.org/10.1016/S0925-4439(00)00042-9] [PMID: 10899441]

Lambert, J-C.; Heath, S.; Even, G.; Campion, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Zelenika, D.; Bullido, M.J.; Tavernier, B.; Letenneur, L.; Bettens, K.; Berr, C.; Pasquier, F.; Fiévet, N.; Barberger-Gateau, P.; Engelborghs, S.; De Deyn, P.; Mateo, I.; Franck, A.; Helisalmi, S.; Porcellini, E.; Hanon, O.; de Pancorbo, M.M.; Lendon, C.; Dufouil, C.; Jaillard, C.; Leveillard, T.; Alvarez, V.; Bosco, P.; Mancuso, M.; Panza, F.; Nacmias, B.; Bossù, P.; Piccardi, P.; Annoni, G.; Seripa, D.; Galimberti, D.; Hannequin, D.; Licastro, F.; Soininen, H.; Ritchie, K.; Blanché, H.; Dartigues, J-F.; Tzourio, C.; Gut, I.; Van Broeckhoven, C.; Alpérovitch, A.; Lathrop, M.; Amouyel, P.; Amouyel, P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat. Genet., 2009, 41(10), 1094-1099.
[http://dx.doi.org/10.1038/ng.439] [PMID: 19734903]

Harold, D.; Abraham, R.; Hollingworth, P.; Sims, R.; Gerrish, A.; Hamshere, M.L.; Pahwa, J.S.; Moskvina, V.; Dowzell, K.; Williams, A.; Jones, N.; Thomas, C.; Stretton, A.; Morgan, A.R.; Lovestone, S.; Powell, J.; Proitsi, P.; Lupton, M.K.; Brayne, C.; Rubinsztein, D.C.; Gill, M.; Lawlor, B.; Lynch, A.; Morgan, K.; Brown, K.S.; Passmore, P.A.; Craig, D.; McGuinness, B.; Todd, S.; Holmes, C.; Mann, D.; Smith, A.D.; Love, S.; Kehoe, P.G.; Hardy, J.; Mead, S.; Fox, N.; Rossor, M.; Collinge, J.; Maier, W.; Jessen, F.; Schürmann, B.; Heun, R.; van den Bussche, H.; Heuser, I.; Kornhuber, J.; Wiltfang, J.; Dichgans, M.; Frölich, L.; Hampel, H.; Hüll, M.; Rujescu, D.; Goate, A.M.; Kauwe, J.S.K.; Cruchaga, C.; Nowotny, P.; Morris, J.C.; Mayo, K.; Sleegers, K.; Bettens, K.; Engelborghs, S.; De Deyn, P.P.; Van Broeckhoven, C.; Livingston, G.; Bass, N.J.; Gurling, H.; McQuillin, A.; Gwilliam, R.; Deloukas, P.; Al-Chalabi, A.; Shaw, C.E.; Tsolaki, M.; Singleton, A.B.; Guerreiro, R.; Mühleisen, T.W.; Nöthen, M.M.; Moebus, S.; Jöckel, K-H.; Klopp, N.; Wichmann, H-E.; Carrasquillo, M.M.; Pankratz, V.S.; Younkin, S.G.; Holmans, P.A.; O’Donovan, M.; Owen, M.J.; Williams, J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat. Genet., 2009, 41(10), 1088-1093.
[http://dx.doi.org/10.1038/ng.440] [PMID: 19734902]

Uddin, M.S.; Kabir, M.T.; Begum, M.M.; Islam, M.S.; Behl, T.; Ashraf, M.G.M. Exploring the role of clu in the pathogenesis of Alzheimer’s disease. Neurotox. Res., 2020, 38(4), 1062.

Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol., 2018, 14, 450-464.
[http://dx.doi.org/10.1016/j.redox.2017.10.014] [PMID: 29080524]

Uddin, M.S.; Upaganlawar, A.B. Oxidative stress and antioxidant defense: Biomedical value in health and diseases; Nova Science Publishers: USA, 2019.

Jones, S.V.; Kounatidis, I. Nuclear factor-kappa b and alzheimer disease, unifying genetic and environmental risk factors from cell to humans. Front. Immunol., 2017, 8, 1805.
[http://dx.doi.org/10.3389/fimmu.2017.01805] [PMID: 29312321]

Tilstra, J.S.; Clauson, C.L.; Niedernhofer, L.J.; Robbins, P.D. NF-κB in Aging and Disease. Aging Dis., 2011, 2(6), 449-465.
[PMID: 22396894]

Thakurta, I.G.; Chattopadhyay, M.; Ghosh, A.; Chakrabarti, S. Dietary supplementation with N-acetyl cysteine, α-tocopherol and α-lipoic acid reduces the extent of oxidative stress and proinflammatory state in aged rat brain. Biogerontology, 2012, 13(5), 479-488.
[http://dx.doi.org/10.1007/s10522-012-9392-5] [PMID: 22851277]

Morgan, M.J.; Liu, Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res., 2011, 21(1), 103-115.
[http://dx.doi.org/10.1038/cr.2010.178] [PMID: 21187859]

Kaltschmidt, B.; Uherek, M.; Volk, B.; Baeuerle, P.A.; Kaltschmidt, C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1997, 94(6), 2642-2647.
[http://dx.doi.org/10.1073/pnas.94.6.2642] [PMID: 9122249]

Kitamura, Y.; Shimohama, S.; Ota, T.; Matsuoka, Y.; Nomura, Y.; Taniguchi, T. Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer’s disease brains. Neurosci. Lett., 1997, 237(1), 17-20.
[http://dx.doi.org/10.1016/S0304-3940(97)00797-0] [PMID: 9406869]

Terai, K.; Matsuo, A.; McGeer, P.L. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer’s disease. Brain Res., 1996, 735(1), 159-168.
[http://dx.doi.org/10.1016/0006-8993(96)00310-1] [PMID: 8905182]

Cai, Z.; Zhao, B.; Ratka, A. Oxidative stress and β-amyloid protein in Alzheimer’s disease. Neuromol. Med., 2011, 13(4), 223-250.
[http://dx.doi.org/10.1007/s12017-011-8155-9] [PMID: 21901428]

Sivandzade, F.; Prasad, S.; Bhalerao, A.; Cucullo, L. NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches. Redox Biol., 2019, 21101059
[http://dx.doi.org/10.1016/j.redox.2018.11.017] [PMID: 30576920]

Carrero, I.; Gonzalo, M.R.; Martin, B.; Sanz-Anquela, J.M.; Arévalo-Serrano, J.; Gonzalo-Ruiz, A. Oligomers of β-amyloid protein (Aβ1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1β, tumour necrosis factor-α, and a nuclear factor κ-B mechanism in the rat brain. Exp. Neurol., 2012, 236(2), 215-227.
[http://dx.doi.org/10.1016/j.expneurol.2012.05.004] [PMID: 22617488]

Chen, J.; Zhou, Y.; Mueller-Steiner, S.; Chen, L-F.; Kwon, H.; Yi, S.; Mucke, L.; Gan, L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem., 2005, 280(48), 40364-40374.
[http://dx.doi.org/10.1074/jbc.M509329200] [PMID: 16183991]

Chen, X-F.; Zhang, Y.W.; Xu, H.; Bu, G. Transcriptional regulation and its misregulation in Alzheimer’s disease. Mol. Brain, 2013, 6, 44.
[http://dx.doi.org/10.1186/1756-6606-6-44] [PMID: 24144318]

Vodovotz, Y.; Lucia, M.S.; Flanders, K.C.; Chesler, L.; Xie, Q.W.; Smith, T.W.; Weidner, J.; Mumford, R.; Webber, R.; Nathan, C.; Roberts, A.B.; Lippa, C.F.; Sporn, M.B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer’s disease. J. Exp. Med., 1996, 184(4), 1425-1433.
[http://dx.doi.org/10.1084/jem.184.4.1425] [PMID: 8879214]

Nathan, C.; Calingasan, N.; Nezezon, J.; Ding, A.; Lucia, M.S.; La Perle, K.; Fuortes, M.; Lin, M.; Ehrt, S.; Kwon, N.S.; Chen, J.; Vodovotz, Y.; Kipiani, K.; Beal, M.F. Protection from Alzheimer’s-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J. Exp. Med., 2005, 202(9), 1163-1169.
[http://dx.doi.org/10.1084/jem.20051529] [PMID: 16260491]

Ansari, M.A.; Scheff, S.W. NADPH-oxidase activation and cognition in Alzheimer disease progression. Free Radic. Biol. Med., 2011, 51(1), 171-178.
[http://dx.doi.org/10.1016/j.freeradbiomed.2011.03.025] [PMID: 21457777]

Jekabsone, A.; Mander, P.K.; Tickler, A.; Sharpe, M.; Brown, G.C. Fibrillar beta-amyloid peptide Abeta1-40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. J. Neuroinflammation, 2006, 3, 24.
[http://dx.doi.org/10.1186/1742-2094-3-24] [PMID: 16959029]

Choi, S-H.; Aid, S.; Kim, H-W.; Jackson, S.H.; Bosetti, F. Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J. Neurochem., 2012, 120(2), 292-301.
[http://dx.doi.org/10.1111/j.1471-4159.2011.07572.x] [PMID: 22050439]

Mander, P.; Brown, G.C. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J. Neuroinflammation, 2005, 2, 20.
[http://dx.doi.org/10.1186/1742-2094-2-20] [PMID: 16156895]

Butterfield, D.A.; Reed, T.T.; Perluigi, M.; De Marco, C.; Coccia, R.; Keller, J.N.; Markesbery, W.R.; Sultana, R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer’s disease. Brain Res., 2007, 1148, 243-248.
[http://dx.doi.org/10.1016/j.brainres.2007.02.084] [PMID: 17395167]

Cho, D.-H.; Nakamura, T.; Fang, J.; Cieplak, P.; Godzik, A.; Gu, Z.; Lipton, S.A. S-nitrosylation of drp1 mediates β-amyloid-related mitochondrial fission and neuronal injury. Science (80-. ), 2009, 324, 102-105..

Kummer, M.P.; Hermes, M.; Delekarte, A.; Hammerschmidt, T.; Kumar, S.; Terwel, D.; Walter, J.; Pape, H.C.; König, S.; Roeber, S.; Jessen, F.; Klockgether, T.; Korte, M.; Heneka, M.T. Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron, 2011, 71(5), 833-844.
[http://dx.doi.org/10.1016/j.neuron.2011.07.001] [PMID: 21903077]

Thiabaud, G.; Pizzocaro, S.; Garcia-Serres, R.; Latour, J-M.; Monzani, E.; Casella, L. Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress. Angew. Chem. Int. Ed. Engl., 2013, 52(31), 8041-8044.
[http://dx.doi.org/10.1002/anie.201302989] [PMID: 23788407]

Rius-Pérez, S.; Tormos, A.M.; Pérez, S.; Taléns-Visconti, R. Vascular pathology: Cause or effect in Alzheimer disease? Neurologia (Engl Ed), 2018, 33(2), 112-120.
[http://dx.doi.org/10.1016/j.nrleng.2015.07.008] [PMID: 26385017]

Attems, J.; Jellinger, K.A. The overlap between vascular disease and Alzheimer’s disease--lessons from pathology. BMC Med., 2014, 12, 206.
[http://dx.doi.org/10.1186/s12916-014-0206-2] [PMID: 25385447]

Iadecola, C. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat. Rev. Neurosci., 2004, 5(5), 347-360.
[http://dx.doi.org/10.1038/nrn1387] [PMID: 15100718]

Shin, H.K.; Jones, P.B.; Garcia-Alloza, M.; Borrelli, L.; Greenberg, S.M.; Bacskai, B.J.; Frosch, M.P.; Hyman, B.T.; Moskowitz, M.A.; Ayata, C. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain, 2007, 130(Pt 9), 2310-2319.
[http://dx.doi.org/10.1093/brain/awm156] [PMID: 17638859]

Petzold, G.C.; Murthy, V.N. Role of astrocytes in neurovascular coupling. Neuron, 2011, 71(5), 782-797.
[http://dx.doi.org/10.1016/j.neuron.2011.08.009] [PMID: 21903073]

Jarre, A.; Gowert, N.S.; Donner, L.; Münzer, P.; Klier, M.; Borst, O.; Schaller, M.; Lang, F.; Korth, C.; Elvers, M. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer’s disease. Cell. Signal., 2014, 26(9), 2040-2050.
[http://dx.doi.org/10.1016/j.cellsig.2014.05.019] [PMID: 24928203]

Deane, R.; Du Yan, S.; Submamaryan, R.K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Schmidt, A.M.; Armstrong, D.L.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.; Kindy, M.; Stern, D.; Zlokovic, B. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med., 2003, 9(7), 907-913.
[http://dx.doi.org/10.1038/nm890] [PMID: 12808450]

Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat. Rev. Neurosci., 2011, 12(12), 723-738.
[http://dx.doi.org/10.1038/nrn3114] [PMID: 22048062]

Aguzzi, A.; Barres, B.A.; Bennett, M.L. Microglia: Scapegoat, saboteur, or something else? Science (80- ), 2013, 339, 156-161.,

Butovsky, O.; Jedrychowski, M.P.; Moore, C.S.; Cialic, R.; Lanser, A.J.; Gabriely, G.; Koeglsperger, T.; Dake, B.; Wu, P.M.; Doykan, C.E.; Fanek, Z.; Liu, L.; Chen, Z.; Rothstein, J.D.; Ransohoff, R.M.; Gygi, S.P.; Antel, J.P.; Weiner, H.L. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci., 2014, 17(1), 131-143.
[http://dx.doi.org/10.1038/nn.3599] [PMID: 24316888]

Lambert, J-C.; Ibrahim-Verbaas, C.A.; Harold, D.; Naj, A.C.; Sims, R.; Bellenguez, C.; DeStafano, A.L.; Bis, J.C.; Beecham, G.W.; Grenier-Boley, B.; Russo, G.; Thorton-Wells, T.A.; Jones, N.; Smith, A.V.; Chouraki, V.; Thomas, C.; Ikram, M.A.; Zelenika, D.; Vardarajan, B.N.; Kamatani, Y.; Lin, C.F.; Gerrish, A.; Schmidt, H.; Kunkle, B.; Dunstan, M.L.; Ruiz, A.; Bihoreau, M.T.; Choi, S.H.; Reitz, C.; Pasquier, F.; Cruchaga, C.; Craig, D.; Amin, N.; Berr, C.; Lopez, O.L.; De Jager, P.L.; Deramecourt, V.; Johnston, J.A.; Evans, D.; Lovestone, S.; Letenneur, L.; Morón, F.J.; Rubinsztein, D.C.; Eiriksdottir, G.; Sleegers, K.; Goate, A.M.; Fiévet, N.; Huentelman, M.W.; Gill, M.; Brown, K.; Kamboh, M.I.; Keller, L.; Barberger-Gateau, P.; McGuiness, B.; Larson, E.B.; Green, R.; Myers, A.J.; Dufouil, C.; Todd, S.; Wallon, D.; Love, S.; Rogaeva, E.; Gallacher, J.; St George-Hyslop, P.; Clarimon, J.; Lleo, A.; Bayer, A.; Tsuang, D.W.; Yu, L.; Tsolaki, M.; Bossù, P.; Spalletta, G.; Proitsi, P.; Collinge, J.; Sorbi, S.; Sanchez-Garcia, F.; Fox, N.C.; Hardy, J.; Deniz Naranjo, M.C.; Bosco, P.; Clarke, R.; Brayne, C.; Galimberti, D.; Mancuso, M.; Matthews, F.; Moebus, S.; Mecocci, P.; Del Zompo, M.; Maier, W.; Hampel, H.; Pilotto, A.; Bullido, M.; Panza, F.; Caffarra, P.; Nacmias, B.; Gilbert, J.R.; Mayhaus, M.; Lannefelt, L.; Hakonarson, H.; Pichler, S.; Carrasquillo, M.M.; Ingelsson, M.; Beekly, D.; Alvarez, V.; Zou, F.; Valladares, O.; Younkin, S.G.; Coto, E.; Hamilton-Nelson, K.L.; Gu, W.; Razquin, C.; Pastor, P.; Mateo, I.; Owen, M.J.; Faber, K.M.; Jonsson, P.V.; Combarros, O.; O’Donovan, M.C.; Cantwell, L.B.; Soininen, H.; Blacker, D.; Mead, S.; Mosley, T.H., Jr; Bennett, D.A.; Harris, T.B.; Fratiglioni, L.; Holmes, C.; de Bruijn, R.F.; Passmore, P.; Montine, T.J.; Bettens, K.; Rotter, J.I.; Brice, A.; Morgan, K.; Foroud, T.M.; Kukull, W.A.; Hannequin, D.; Powell, J.F.; Nalls, M.A.; Ritchie, K.; Lunetta, K.L.; Kauwe, J.S.; Boerwinkle, E.; Riemenschneider, M.; Boada, M.; Hiltuenen, M.; Martin, E.R.; Schmidt, R.; Rujescu, D.; Wang, L.S.; Dartigues, J.F.; Mayeux, R.; Tzourio, C.; Hofman, A.; Nöthen, M.M.; Graff, C.; Psaty, B.M.; Jones, L.; Haines, J.L.; Holmans, P.A.; Lathrop, M.; Pericak-Vance, M.A.; Launer, L.J.; Farrer, L.A.; van Duijn, C.M.; Van Broeckhoven, C.; Moskvina, V.; Seshadri, S.; Williams, J.; Schellenberg, G.D.; Amouyel, P.; Lathrop, M.; Pericak-Vance, M.A.; Launer, L.J.; Farrer, L.A.; van Duijn, C.M.; Van Broeckhoven, C.; Moskvina, V.; Seshadri, S.; Williams, J.; Schellenberg, G.D.; Amouyel, P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet., 2013, 45(12), 1452-1458.
[http://dx.doi.org/10.1038/ng.2802] [PMID: 24162737]

Friedman, B.A.; Srinivasan, K.; Ayalon, G.; Meilandt, W.J.; Lin, H.; Huntley, M.A.; Cao, Y.; Lee, S.H.; Haddick, P.C.G.; Ngu, H.; Modrusan, Z.; Larson, J.L.; Kaminker, J.S.; van der Brug, M.P.; Hansen, D.V. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer’s disease not evident in mouse models. Cell Rep., 2018, 22(3), 832-847.
[http://dx.doi.org/10.1016/j.celrep.2017.12.066] [PMID: 29346778]

Keren-Shaul, H.; Spinrad, A.; Weiner, A.; Matcovitch-Natan, O.; Dvir-Szternfeld, R.; Ulland, T.K.; David, E.; Baruch, K.; Lara-Astaiso, D.; Toth, B.; Itzkovitz, S.; Colonna, M.; Schwartz, M.; Amit, I. A unique microglia type associated with restricting development of alzheimer’s disease. Cell, 2017, 169(7), 1276-1290.e17.
[http://dx.doi.org/10.1016/j.cell.2017.05.018] [PMID: 28602351]

Zhao, Y.; Wu, X.; Li, X.; Jiang, L.L.; Gui, X.; Liu, Y.; Sun, Y.; Zhu, B.; Piña-Crespo, J.C.; Zhang, M.; Zhang, N.; Chen, X.; Bu, G.; An, Z.; Huang, T.Y.; Xu, H. TREM2 is a receptor for β-amyloid that mediates microglial function. Neuron, 2018, 97(5), 1023-1031.e7.
[http://dx.doi.org/10.1016/j.neuron.2018.01.031] [PMID: 29518356]

Zhong, L.; Wang, Z.; Wang, D.; Wang, Z.; Martens, Y.A.; Wu, L.; Xu, Y.; Wang, K.; Li, J.; Huang, R.; Can, D.; Xu, H.; Bu, G.; Chen, X.F. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol. Neurodegener., 2018, 13(1), 15.
[http://dx.doi.org/10.1186/s13024-018-0247-7] [PMID: 29587871]

Ahyayauch, H.; Raab, M.; Busto, J.V.; Andraka, N.; Arrondo, J.R.; Masserini, M.; Tvaroska, I.; Goñi, F.M. Binding of β-amyloid (1-42) peptide to negatively charged phospholipid membranes in the liquid-ordered state: modeling and experimental studies. Biophys. J., 2012, 103(3), 453-463.
[http://dx.doi.org/10.1016/j.bpj.2012.06.043] [PMID: 22947861]

Nagarathinam, A.; Höflinger, P.; Bühler, A.; Schäfer, C.; McGovern, G.; Jeffrey, M.; Staufenbiel, M.; Jucker, M.; Baumann, F. Membrane-anchored Aβ accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice. J. Neurosci., 2013, 33(49), 19284-19294.
[http://dx.doi.org/10.1523/JNEUROSCI.2542-13.2013] [PMID: 24305824]

Wang, Y.; Cella, M.; Mallinson, K.; Ulrich, J.D.; Young, K.L.; Robinette, M.L.; Gilfillan, S.; Krishnan, G.M.; Sudhakar, S.; Zinselmeyer, B.H.; Holtzman, D.M.; Cirrito, J.R.; Colonna, M. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell, 2015, 160(6), 1061-1071.
[http://dx.doi.org/10.1016/j.cell.2015.01.049] [PMID: 25728668]

Song, W.; Hooli, B.; Mullin, K.; Jin, S.C.; Cella, M.; Ulland, T.K.; Wang, Y.; Tanzi, R.E.; Colonna, M. Alzheimer’s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement., 2017, 13(4), 381-387.
[http://dx.doi.org/10.1016/j.jalz.2016.07.004] [PMID: 27520774]

Terwel, D.; Steffensen, K.R.; Verghese, P.B.; Kummer, M.P.; Gustafsson, J.Å.; Holtzman, D.M.; Heneka, M.T. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J. Neurosci., 2011, 31(19), 7049-7059.
[http://dx.doi.org/10.1523/JNEUROSCI.6546-10.2011] [PMID: 21562267]

Yeh, F.L.; Wang, Y.; Tom, I.; Gonzalez, L.C.; Sheng, M. TREM2 binds to apolipoproteins, including apoe and clu/apoj, and thereby facilitates uptake of amyloid-beta by microglia. Neuron, 2016, 91(2), 328-340.
[http://dx.doi.org/10.1016/j.neuron.2016.06.015] [PMID: 27477018]

Song, W.M.; Joshita, S.; Zhou, Y.; Ulland, T.K.; Gilfillan, S.; Colonna, M. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med., 2018, 215(3), 745-760.
[http://dx.doi.org/10.1084/jem.20171529] [PMID: 29321225]

Guerreiro, R.; Wojtas, A.; Bras, J.; Carrasquillo, M.; Rogaeva, E.; Majounie, E.; Cruchaga, C.; Sassi, C.; Kauwe, J.S.K.; Younkin, S.; Hazrati, L.; Collinge, J.; Pocock, J.; Lashley, T.; Williams, J.; Lambert, J-C.; Amouyel, P.; Goate, A.; Rademakers, R.; Morgan, K.; Powell, J.; St George-Hyslop, P.; Singleton, A.; Hardy, J. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med., 2013, 368(2), 117-127.
[http://dx.doi.org/10.1056/NEJMoa1211851] [PMID: 23150934]

Jonsson, T.; Stefansson, H.; Steinberg, S.; Jonsdottir, I.; Jonsson, P.V.; Snaedal, J.; Bjornsson, S.; Huttenlocher, J.; Levey, A.I.; Lah, J.J.; Rujescu, D.; Hampel, H.; Giegling, I.; Andreassen, O.A.; Engedal, K.; Ulstein, I.; Djurovic, S.; Ibrahim-Verbaas, C.; Hofman, A.; Ikram, M.A.; van Duijn, C.M.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med., 2013, 368(2), 107-116.
[http://dx.doi.org/10.1056/NEJMoa1211103] [PMID: 23150908]

Mori, Y.; Yoshino, Y.; Ochi, S.; Yamazaki, K.; Kawabe, K.; Abe, M.; Kitano, T.; Ozaki, Y.; Yoshida, T.; Numata, S.; Mori, T.; Iga, J.; Kuroda, N.; Ohmori, T.; Ueno, S. TREM2 mrna expression in leukocytes is increased in Alzheimer’s disease and schizophrenia. PLoS One, 2015, 10(9)e0136835
[http://dx.doi.org/10.1371/journal.pone.0136835] [PMID: 26332043]

Paloneva, J.; Kestilä, M.; Wu, J.; Salminen, A.; Böhling, T.; Ruotsalainen, V.; Hakola, P.; Bakker, A.B.H.; Phillips, J.H.; Pekkarinen, P.; Lanier, L.L.; Timonen, T.; Peltonen, L. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat. Genet., 2000, 25(3), 357-361.
[http://dx.doi.org/10.1038/77153] [PMID: 10888890]

Liu, Z.; Condello, C.; Schain, A.; Harb, R.; Grutzendler, J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis. J. Neurosci., 2010, 30(50), 17091-17101.
[http://dx.doi.org/10.1523/JNEUROSCI.4403-10.2010] [PMID: 21159979]

Bhaskar, K.; Konerth, M.; Kokiko-Cochran, O.N.; Cardona, A.; Ransohoff, R.M.; Lamb, B.T. Regulation of tau pathology by the microglial fractalkine receptor. Neuron, 2010, 68(1), 19-31.
[http://dx.doi.org/10.1016/j.neuron.2010.08.023] [PMID: 20920788]

Jiang, T.; Zhang, Y.D.; Chen, Q.; Gao, Q.; Zhu, X.C.; Zhou, J.S.; Shi, J.Q.; Lu, H.; Tan, L.; Yu, J.T. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology, 2016, 105, 196-206.
[http://dx.doi.org/10.1016/j.neuropharm.2016.01.028] [PMID: 26802771]

Jay, T.R.; Hirsch, A.M.; Broihier, M.L.; Miller, C.M.; Neilson, L.E.; Ransohoff, R.M.; Lamb, B.T.; Landreth, G.E. Disease progression-dependent effects of trem2 deficiency in a mouse model of Alzheimer’s disease. J. Neurosci., 2017, 37(3), 637-647.
[http://dx.doi.org/10.1523/JNEUROSCI.2110-16.2016] [PMID: 28100745]

Zhang, B.; Gaiteri, C.; Bodea, L-G.; Wang, Z.; McElwee, J.; Podtelezhnikov, A.A.; Zhang, C.; Xie, T.; Tran, L.; Dobrin, R.; Fluder, E.; Clurman, B.; Melquist, S.; Narayanan, M.; Suver, C.; Shah, H.; Mahajan, M.; Gillis, T.; Mysore, J.; MacDonald, M.E.; Lamb, J.R.; Bennett, D.A.; Molony, C.; Stone, D.J.; Gudnason, V.; Myers, A.J.; Schadt, E.E.; Neumann, H.; Zhu, J.; Emilsson, V. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell, 2013, 153(3), 707-720.
[http://dx.doi.org/10.1016/j.cell.2013.03.030] [PMID: 23622250]

Tarkowski, E.; Andreasen, N.; Tarkowski, A.; Blennow, K. Intrathecal inflammation precedes development of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry, 2003, 74(9), 1200-1205.
[http://dx.doi.org/10.1136/jnnp.74.9.1200] [PMID: 12933918]

Brosseron, F.; Krauthausen, M.; Kummer, M.; Heneka, M.T. Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: A comparative overview. Mol. Neurobiol., 2014, 50(2), 534-544.
[http://dx.doi.org/10.1007/s12035-014-8657-1] [PMID: 24567119]

Krstic, D.; Madhusudan, A.; Doehner, J.; Vogel, P.; Notter, T.; Imhof, C.; Manalastas, A.; Hilfiker, M.; Pfister, S.; Schwerdel, C.; Riether, C.; Meyer, U.; Knuesel, I. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflammation, 2012, 9, 151.
[http://dx.doi.org/10.1186/1742-2094-9-151] [PMID: 22747753]

Gandy, S.; Heppner, F.L. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron, 2013, 78(4), 575-577.
[http://dx.doi.org/10.1016/j.neuron.2013.05.007] [PMID: 23719156]

Perry, V.H.; Holmes, C. Microglial priming in neurodegenerative disease. Nat. Rev. Neurol., 2014, 10(4), 217-224.
[http://dx.doi.org/10.1038/nrneurol.2014.38] [PMID: 24638131]

Heneka, M.T.; Kummer, M.P.; Latz, E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol., 2014, 14(7), 463-477.
[http://dx.doi.org/10.1038/nri3705] [PMID: 24962261]

Cunningham, C. Microglia and neurodegeneration: the role of systemic inflammation. Glia, 2013, 61(1), 71-90.
[http://dx.doi.org/10.1002/glia.22350] [PMID: 22674585]

Sudduth, T.L.; Schmitt, F.A.; Nelson, P.T.; Wilcock, D.M. Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol. Aging, 2013, 34(4), 1051-1059.
[http://dx.doi.org/10.1016/j.neurobiolaging.2012.09.012] [PMID: 23062700]

Krstic, D.; Knuesel, I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol., 2013, 9(1), 25-34.
[http://dx.doi.org/10.1038/nrneurol.2012.236] [PMID: 23183882]

Hickman, S.E.; El Khoury, J. TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem. Pharmacol., 2014, 88(4), 495-498.
[http://dx.doi.org/10.1016/j.bcp.2013.11.021] [PMID: 24355566]

Perry, V.H. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol., 2010, 120(3), 277-286.
[http://dx.doi.org/10.1007/s00401-010-0722-x] [PMID: 20644946]

Holmes, C.; Cunningham, C.; Zotova, E.; Woolford, J.; Dean, C.; Kerr, S.; Culliford, D.; Perry, V.H. Systemic inflammation and disease progression in Alzheimer disease. Neurology, 2009, 73(10), 768-774.
[http://dx.doi.org/10.1212/WNL.0b013e3181b6bb95] [PMID: 19738171]

Cribbs, D.H.; Berchtold, N.C.; Perreau, V.; Coleman, P.D.; Rogers, J.; Tenner, A.J.; Cotman, C.W. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J. Neuroinflammation, 2012, 9, 179.
[http://dx.doi.org/10.1186/1742-2094-9-179] [PMID: 22824372]

Schwartz, M.; Shechter, R. Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol., 2010, 6(7), 405-410.
[http://dx.doi.org/10.1038/nrneurol.2010.71] [PMID: 20531383]

Lo, A.W.; Ho, C.; Cummings, J.; Kosik, K.S. Parallel discovery of Alzheimer’s therapeutics. Sci. Transl. Med., 2014, 6(241)241cm5
[http://dx.doi.org/10.1126/scitranslmed.3008228] [PMID: 24944190]

Vom Berg, J.; Prokop, S.; Miller, K.R.; Obst, J.; Kälin, R.E.; Lopategui-Cabezas, I.; Wegner, A.; Mair, F.; Schipke, C.G.; Peters, O.; Winter, Y.; Becher, B.; Heppner, F.L. Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat. Med., 2012, 18(12), 1812-1819.
[http://dx.doi.org/10.1038/nm.2965] [PMID: 23178247]

Hu, W.T.; Holtzman, D.M.; Fagan, A.M.; Shaw, L.M.; Perrin, R.; Arnold, S.E.; Grossman, M.; Xiong, C.; Craig-Schapiro, R.; Clark, C.M.; Pickering, E.; Kuhn, M.; Chen, Y.; Van Deerlin, V.M.; McCluskey, L.; Elman, L.; Karlawish, J.; Chen-Plotkin, A.; Hurtig, H.I.; Siderowf, A.; Swenson, F.; Lee, V.M.Y.; Morris, J.C.; Trojanowski, J.Q.; Soares, H. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2012, 79(9), 897-905.
[http://dx.doi.org/10.1212/WNL.0b013e318266fa70] [PMID: 22855860]

Tan, M.S.; Yu, J.T.; Jiang, T.; Zhu, X.C.; Guan, H.S.; Tan, L. IL12/23 p40 inhibition ameliorates Alzheimer’s disease-associated neuropathology and spatial memory in SAMP8 mice. J. Alzheimers Dis., 2014, 38(3), 633-646.
[http://dx.doi.org/10.3233/JAD-131148] [PMID: 24047617]

Liu, Y.; Yu, J.T.; Zhang, W.; Zong, Y.; Lu, R.C.; Zhou, J.; Tan, L. Interleukin-23 receptor polymorphisms are associated with Alzheimer’s disease in Han Chinese. J. Neuroimmunol., 2014, 271(1-2), 43-48.
[http://dx.doi.org/10.1016/j.jneuroim.2014.03.013] [PMID: 24703098]

Papassotiropoulos, A.; Bagli, M.; Jessen, F.; Bayer, T.A.; Maier, W.; Rao, M.L.; Heun, R. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer’s disease. Ann. Neurol., 1999, 45(5), 666-668.
[http://dx.doi.org/10.1002/1531-8249(199905)45:5<666:AID-ANA18>3.0.CO;2-3] [PMID: 10319892]

Cojocaru, I.M.; Cojocaru, M.; Miu, G.; Sapira, V. Study of interleukin-6 production in Alzheimer’s disease. Rom. J. Intern. Med., 2011, 49(1), 55-58.
[PMID: 22026253]

Ng, A.; Tam, W.W.; Zhang, M.W.; Ho, C.S.; Husain, S.F.; McIntyre, R.S.; Ho, R.C. IL-1β, IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer’s disease: Systematic Review and Meta-Analysis. Sci. Rep., 2018, 8(1), 12050.
[http://dx.doi.org/10.1038/s41598-018-30487-6] [PMID: 30104698]

Kleinberger, G.; Yamanishi, Y.; Suárez-Calvet, M.; Czirr, E.; Lohmann, E.; Cuyvers, E.; Struyfs, H.; Pettkus, N.; Wenninger-Weinzierl, A.; Mazaheri, F.; Tahirovic, S.; Lleó, A.; Alcolea, D.; Fortea, J.; Willem, M.; Lammich, S.; Molinuevo, J.L.; Sánchez-Valle, R.; Antonell, A.; Ramirez, A.; Heneka, M.T.; Sleegers, K.; van der Zee, J.; Martin, J.J.; Engelborghs, S.; Demirtas-Tatlidede, A.; Zetterberg, H.; Van Broeckhoven, C.; Gurvit, H.; Wyss-Coray, T.; Hardy, J.; Colonna, M.; Haass, C. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med., 2014, 6(243)243ra86
[http://dx.doi.org/10.1126/scitranslmed.3009093] [PMID: 24990881]

Jay, T.R.; Miller, C.M.; Cheng, P.J.; Graham, L.C.; Bemiller, S.; Broihier, M.L.; Xu, G.; Margevicius, D.; Karlo, J.C.; Sousa, G.L.; Cotleur, A.C.; Butovsky, O.; Bekris, L.; Staugaitis, S.M.; Leverenz, J.B.; Pimplikar, S.W.; Landreth, G.E.; Howell, G.R.; Ransohoff, R.M.; Lamb, B.T. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J. Exp. Med., 2015, 212(3), 287-295.
[http://dx.doi.org/10.1084/jem.20142322] [PMID: 25732305]

Baleriola, J.; Walker, C.A.; Jean, Y.Y.; Crary, J.F.; Troy, C.M.; Nagy, P.L.; Hengst, U. Axonally synthesized ATF4 transmits a neurodegenerative signal across brain regions. Cell, 2014, 158(5), 1159-1172.
[http://dx.doi.org/10.1016/j.cell.2014.07.001] [PMID: 25171414]

Bradshaw, E.M.; Chibnik, L.B.; Keenan, B.T.; Ottoboni, L.; Raj, T.; Tang, A.; Rosenkrantz, L.L.; Imboywa, S.; Lee, M.; Von Korff, A.; Morris, M.C.; Evans, D.A.; Johnson, K.; Sperling, R.A.; Schneider, J.A.; Bennett, D.A.; De Jager, P.L. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat. Neurosci., 2013, 16(7), 848-850.
[http://dx.doi.org/10.1038/nn.3435] [PMID: 23708142]

Naj, A.C.; Jun, G.; Beecham, G.W.; Wang, L.S.; Vardarajan, B.N.; Buros, J.; Gallins, P.J.; Buxbaum, J.D.; Jarvik, G.P.; Crane, P.K.; Larson, E.B.; Bird, T.D.; Boeve, B.F.; Graff-Radford, N.R.; De Jager, P.L.; Evans, D.; Schneider, J.A.; Carrasquillo, M.M.; Ertekin-Taner, N.; Younkin, S.G.; Cruchaga, C.; Kauwe, J.S.K.; Nowotny, P.; Kramer, P.; Hardy, J.; Huentelman, M.J.; Myers, A.J.; Barmada, M.M.; Demirci, F.Y.; Baldwin, C.T.; Green, R.C.; Rogaeva, E.; St George-Hyslop, P.; Arnold, S.E.; Barber, R.; Beach, T.; Bigio, E.H.; Bowen, J.D.; Boxer, A.; Burke, J.R.; Cairns, N.J.; Carlson, C.S.; Carney, R.M.; Carroll, S.L.; Chui, H.C.; Clark, D.G.; Corneveaux, J.; Cotman, C.W.; Cummings, J.L.; DeCarli, C.; DeKosky, S.T.; Diaz-Arrastia, R.; Dick, M.; Dickson, D.W.; Ellis, W.G.; Faber, K.M.; Fallon, K.B.; Farlow, M.R.; Ferris, S.; Frosch, M.P.; Galasko, D.R.; Ganguli, M.; Gearing, M.; Geschwind, D.H.; Ghetti, B.; Gilbert, J.R.; Gilman, S.; Giordani, B.; Glass, J.D.; Growdon, J.H.; Hamilton, R.L.; Harrell, L.E.; Head, E.; Honig, L.S.; Hulette, C.M.; Hyman, B.T.; Jicha, G.A.; Jin, L.W.; Johnson, N.; Karlawish, J.; Karydas, A.; Kaye, J.A.; Kim, R.; Koo, E.H.; Kowall, N.W.; Lah, J.J.; Levey, A.I.; Lieberman, A.P.; Lopez, O.L.; Mack, W.J.; Marson, D.C.; Martiniuk, F.; Mash, D.C.; Masliah, E.; McCormick, W.C.; McCurry, S.M.; McDavid, A.N.; McKee, A.C.; Mesulam, M.; Miller, B.L.; Miller, C.A.; Miller, J.W.; Parisi, J.E.; Perl, D.P.; Peskind, E.; Petersen, R.C.; Poon, W.W.; Quinn, J.F.; Rajbhandary, R.A.; Raskind, M.; Reisberg, B.; Ringman, J.M.; Roberson, E.D.; Rosenberg, R.N.; Sano, M.; Schneider, L.S.; Seeley, W.; Shelanski, M.L.; Slifer, M.A.; Smith, C.D.; Sonnen, J.A.; Spina, S.; Stern, R.A.; Tanzi, R.E.; Trojanowski, J.Q.; Troncoso, J.C.; Van Deerlin, V.M.; Vinters, H.V.; Vonsattel, J.P.; Weintraub, S.; Welsh-Bohmer, K.A.; Williamson, J.; Woltjer, R.L.; Cantwell, L.B.; Dombroski, B.A.; Beekly, D.; Lunetta, K.L.; Martin, E.R.; Kamboh, M.I.; Saykin, A.J.; Reiman, E.M.; Bennett, D.A.; Morris, J.C.; Montine, T.J.; Goate, A.M.; Blacker, D.; Tsuang, D.W.; Hakonarson, H.; Kukull, W.A.; Foroud, T.M.; Haines, J.L.; Mayeux, R.; Pericak-Vance, M.A.; Farrer, L.A.; Schellenberg, G.D. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet., 2011, 43(5), 436-441.
[http://dx.doi.org/10.1038/ng.801] [PMID: 21460841]

Thambisetty, M.; An, Y.; Nalls, M.; Sojkova, J.; Swaminathan, S.; Zhou, Y.; Singleton, A.B.; Wong, D.F.; Ferrucci, L.; Saykin, A.J.; Resnick, S.M. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol. Psychiatry, 2013, 73(5), 422-428.
[http://dx.doi.org/10.1016/j.biopsych.2012.08.015] [PMID: 23022416]

Mahmoudi, R.; Feldman, S.; Kisserli, A.; Duret, V.; Tabary, T.; Bertholon, L.A.; Badr, S.; Nonnonhou, V.; Cesar, A.; Neuraz, A.; Novella, J.L.; Cohen, J.H.M. Inherited and acquired decrease in complement receptor 1 (cr1) density on red blood cells associated with high levels of soluble cr1 in alzheimer’s disease. Int. J. Mol. Sci., 2018, 19(8), 19.
[http://dx.doi.org/10.3390/ijms19082175] [PMID: 30044434]

Yamanaka, M.; Ishikawa, T.; Griep, A.; Axt, D.; Kummer, M.P.; Heneka, M.T. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neurosci., 2012, 32(48), 17321-17331.
[http://dx.doi.org/10.1523/JNEUROSCI.1569-12.2012] [PMID: 23197723]

Cramer, P.E.; Cirrito, J.R.; Wesson, D.W.; Lee, C.Y.D.; Karlo, J.C.; Zinn, A.E.; Casali, B.T.; Restivo, J.L.; Goebel, W.D.; James, M.J.; Brunden, K.R.; Wilson, D.A.; Landreth, G.E. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in ad mouse models.Science (80-.),, 2012, 335, 1503-1506.

Sheedy, F.J.; Grebe, A.; Rayner, K.J.; Kalantari, P.; Ramkhelawon, B.; Carpenter, S.B.; Becker, C.E.; Ediriweera, H.N.; Mullick, A.E.; Golenbock, D.T.; Stuart, L.M.; Latz, E.; Fitzgerald, K.A.; Moore, K.J. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol., 2013, 14(8), 812-820.
[http://dx.doi.org/10.1038/ni.2639] [PMID: 23812099]

Ries, M.; Sastre, M. Mechanisms of aβ clearance and degradation by glial cells. Front. Aging Neurosci., 2016, 8, 160.
[http://dx.doi.org/10.3389/fnagi.2016.00160] [PMID: 27458370]

Fassbender, K.; Walter, S.; Kühl, S.; Landmann, R.; Ishii, K.; Bertsch, T.; Stalder, A.K.; Muehlhauser, F.; Liu, Y.; Ulmer, A.J.; Rivest, S.; Lentschat, A.; Gulbins, E.; Jucker, M.; Staufenbiel, M.; Brechtel, K.; Walter, J.; Multhaup, G.; Penke, B.; Adachi, Y.; Hartmann, T.; Beyreuther, K. The LPS receptor (CD14) links innate immunity with Alzheimer’s disease. FASEB J., 2004, 18(1), 203-205.
[http://dx.doi.org/10.1096/fj.03-0364fje] [PMID: 14597556]

Reed-Geaghan, E.G.; Reed, Q.W.; Cramer, P.E.; Landreth, G.E. Deletion of CD14 attenuates Alzheimer’s disease pathology by influencing the brain’s inflammatory milieu. J. Neurosci., 2010, 30(46), 15369-15373.
[http://dx.doi.org/10.1523/JNEUROSCI.2637-10.2010] [PMID: 21084593]

Pase, M.P.; Himali, J.J.; Beiser, A.S.; DeCarli, C.; McGrath, E.R.; Satizabal, C.L.; Aparicio, H.J.; Adams, H.H.H.; Reiner, A.P.; Longstreth, W.T., Jr; Fornage, M.; Tracy, R.P.; Lopez, O.; Psaty, B.M.; Levy, D.; Seshadri, S.; Bis, J.C. Association of CD14 with incident dementia and markers of brain aging and injury. Neurology, 2020, 94(3), e254-e266.
[http://dx.doi.org/10.1212/WNL.0000000000008682] [PMID: 31818907]

Chen, P.; Zhao, W.; Guo, Y.; Xu, J.; Yin, M. CX3CL1/CX3CR1 in alzheimer’s disease: A target for neuroprotection. Biomed Res. Int., 2016, 20168090918

Nash, K.R.; Lee, D.C.; Hunt, J.B., Jr; Morganti, J.M.; Selenica, M.L.; Moran, P.; Reid, P.; Brownlow, M.; Guang, Yu Yang, C.; Savalia, M.; Gemma, C.; Bickford, P.C.; Gordon, M.N.; Morgan, D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol. Aging, 2013, 34(6), 1540-1548.
[http://dx.doi.org/10.1016/j.neurobiolaging.2012.12.011] [PMID: 23332170]

Hickman, S.E.; Allison, E.K.; Coleman, U.; Kingery-Gallagher, N.D.; El Khoury, J. Heterozygous cx3cr1 deficiency in microglia restores neuronal β-amyloid clearance pathways and slows progression of alzheimer’s like-disease in ps1-app mice. Front. Immunol., 2019, 10, 2780.
[http://dx.doi.org/10.3389/fimmu.2019.02780] [PMID: 31849963]

Ryu, J.K.; McLarnon, J.G. Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer’s disease. Neuroreport, 2008, 19(17), 1715-1719.
[http://dx.doi.org/10.1097/WNR.0b013e3283179333] [PMID: 18852683]

Diaz-Hernandez, J.I.; Gomez-Villafuertes, R.; León-Otegui, M.; Hontecillas-Prieto, L.; Del Puerto, A.; Trejo, J.L.; Lucas, J.J.; Garrido, J.J.; Gualix, J.; Miras-Portugal, M.T.; Diaz-Hernandez, M. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through GSK3β and secretases. Neurobiol. Aging, 2012, 33(8), 1816-1828.
[http://dx.doi.org/10.1016/j.neurobiolaging.2011.09.040] [PMID: 22048123]

Frenkel, D.; Wilkinson, K.; Zhao, L.; Hickman, S.E.; Means, T.K.; Puckett, L.; Farfara, D.; Kingery, N.D.; Weiner, H.L.; El Khoury, J. Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease progression. Nat. Commun., 2013, 4, 2030.
[http://dx.doi.org/10.1038/ncomms3030] [PMID: 23799536]

Chen, J-H.; Ke, K-F.; Lu, J-H.; Qiu, Y-H.; Peng, Y-P. Protection of TGF-β1 against neuroinflammation and neurodegeneration in Aβ1-42-induced Alzheimer’s disease model rats. PLoS One, 2015, 10(2)e0116549
[http://dx.doi.org/10.1371/journal.pone.0116549] [PMID: 25658940]

Juraskova, B.; Andrys, C.; Holmerova, I.; Solichova, D.; Hrnciarikova, D.; Vankova, H.; Vasatko, T.; Krejsek, J. Transforming growth factor beta and soluble endoglin in the healthy senior and in Alzheimer’s disease patients. J. Nutr. Health Aging, 2010, 14(9), 758-761.
[http://dx.doi.org/10.1007/s12603-010-0325-1] [PMID: 21085906]

Guerreiro, R.J.; Santana, I.; Brás, J.M.; Santiago, B.; Paiva, A.; Oliveira, C. Peripheral inflammatory cytokines as biomarkers in Alzheimer’s disease and mild cognitive impairment. Neurodegener. Dis., 2007, 4(6), 406-412.
[http://dx.doi.org/10.1159/000107700] [PMID: 17934323]

Coll, R.C.; Robertson, A.A.B.; Chae, J.J.; Higgins, S.C.; Muñoz-Planillo, R.; Inserra, M.C.; Vetter, I.; Dungan, L.S.; Monks, B.G.; Stutz, A.; Croker, D.E.; Butler, M.S.; Haneklaus, M.; Sutton, C.E.; Núñez, G.; Latz, E.; Kastner, D.L.; Mills, K.H.G.; Masters, S.L.; Schroder, K.; Cooper, M.A.; O’Neill, L.A.J. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med., 2015, 21(3), 248-255.
[http://dx.doi.org/10.1038/nm.3806] [PMID: 25686105]

van der Wal, E.A.; Gómez-Pinilla, F.; Cotman, C.W. Transforming growth factor-beta 1 is in plaques in Alzheimer and down pathologies. Neuroreport, 1993, 4(1), 69-72.
[http://dx.doi.org/10.1097/00001756-199301000-00018] [PMID: 8453039]

Wyss-Coray, T.; Lin, C.; Yan, F.; Yu, G.Q.; Rohde, M.; McConlogue, L.; Masliah, E.; Mucke, L. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med., 2001, 7(5), 612-618.
[http://dx.doi.org/10.1038/87945] [PMID: 11329064]

Town, T.; Laouar, Y.; Pittenger, C.; Mori, T.; Szekely, C.A.; Tan, J.; Duman, R.S.; Flavell, R.A. Blocking TGF-β-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med., 2008, 14(6), 681-687.
[http://dx.doi.org/10.1038/nm1781] [PMID: 18516051]

Swardfager, W.; Lanctôt, K.; Rothenburg, L.; Wong, A.; Cappell, J.; Herrmann, N. A meta-analysis of cytokines in Alzheimer’s disease. Biol. Psychiatry, 2010, 68(10), 930-941.
[http://dx.doi.org/10.1016/j.biopsych.2010.06.012] [PMID: 20692646]